, , -
The FDA states that the agency would consider taking action against a compounder for compounding drug products with this bulk drug substance
These early symptoms can be subtle and may progress over time, so seeking medical evaluation is important when they persist or worsen
Available from: Deshpande SH, Muhsinah A, Bin, Bagewadi ZK, Ankad GM, Mahnashi MH, Yaraguppi DA et al
(2011, American Journal of Pathology) reported that IGF-1 had plaque-stabilizing effects in a mouse atherosclerosis model useful as a half-life reference (~20-30 hours) and pathway marker
(1982) Teratogenic study of ethylene and propylene oxide and N-butyl acetate, Richland, Washington, Batelle Pacific Northwest Laboratories (Report No